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TO THE EDITOR: 1 
 2 
In the issue of Circulation Research on July 22nd, we published a Mendelian 3 
randomization study to assess the causal effect of higher adiponectin levels on the risk 4 
of coronary heart disease (CHD) using summary data from large scale genome-wide 5 
association studies (GWAS)1. Overall, our findings are not supportive of the hypothesis 6 
that higher adiponectin levels protect against CHD development. In an editorial related 7 
to our paper2, Turer and Scherer state that “Several major issues with the present 8 
analysis suggest that the conclusions drawn are rather premature”. In this letter, we 9 
discuss the points raised by the authors.  10 
Turer and Scherer point out that one important assumption of Mendelian 11 
randomization is that “SNPs significantly influence the levels of adiponectin”2. Indeed, 12 
the use of weak genetic instruments can not only reduce precision, but also introduce 13 
bias in Mendelian randomization estimates. For this reason, we selected as genetic 14 
instruments the SNPs with the strongest association with adiponectin levels from the 15 
largest GWAS available, the ADIPOGen consortium. The SNPs selected nearby the 16 
ADIPOQ locus, or other highly correlated SNPs, have been previously used in 17 
Mendelian randomization studies and explain about 4%-6% of variation in adiponectin 18 
levels3, 4. Of note this is a higher proportion of variation than SNPs used in Mendelian 19 
randomization studies confirming the causal effect of systolic blood pressure (<1%) on 20 
CHD5. As mentioned in our paper, our instrument for adiponectin gave us more than 21 
97% power to detect an odds ratio of CHD of at least 0.80 per 2.7-fold increment in 22 
circulating adiponectin levels, indicating that we would have been able to detect even 23 
modest clinically relevant effects. 24 
Regarding concerns over the use of different assays for adiponectin2. The 25 
ADIPOGen consortium included 16 cohorts that measured adiponectin using either RIA 26 
or ELISA methods and found highly consistent results when analyses were stratified by 27 
type of assay6. As we noted in our paper, there was little evidence of heterogeneity 28 
between studies for most selected SNPs, indicating that study differences, including 29 
differences in type of assay, are unlikely to have influenced our results. 30 
Turer and Scherer question whether “randomization was successful in 31 
achieving a balance of demographic (…) and clinical characteristics (…)”2. One of the 32 
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core strengths of Mendelian randomization relates to the fact that genetic variants are 33 
not usually correlated with confounding factors, as a result of the mechanisms of 34 
Mendelian inheritance. This has been demonstrated empirically7 and is precisely why 35 
Mendelian randomization is much less vulnerable to confounding than conventional 36 
multivariable regression analysis. The only exception to this would be in the case of 37 
population stratification, where confounding could be introduced by subgroups of 38 
different genetic ancestries. As mentioned in our paper, the GWAS consortia that 39 
contributed to our analyses were largely restricted to individuals of European ancestry 40 
and controlled for population stratification by undertaking double genomic control 41 
(prior and after meta-analysing results), which is in line with good practices of GWAS. 42 
Lastly, we undertook a positive control study using the same CHD data and 43 
demonstrated the expected positive causal effect of LDL-c on CHD.  44 
Turer and Scherer are also concerned that by adjusting for some established 45 
cardiovascular risk factors we might have over-adjusted for factors on the causal path 46 
between adiponectin and CHD2. They seem to have misunderstood our methodological 47 
approach which set out specifically to explore whether these factors were potential 48 
mediators or confounders. First, we showed that SNPs nearby or in the ADIPOQ locus 49 
(conservative approach), which codes for adiponectin, were not related to fasting 50 
insulin, HDL-c, triacylglycerol, waist circumference or body mass index (Table 2 and 51 
Figure 3A). Second, we used a multi-loci set of SNPs (liberal approach) and found that 52 
those SNPs outside of the ADIPOQ locus were associated with other CHD risk factors 53 
and that the results from MR-Egger method supported the presence of horizontal 54 
pleiotropy in the liberal approach. Together these findings strongly suggest that 55 
adiponectin does not causally affect these risk factors and therefore they cannot 56 
mediate any of its causal effects on disease outcomes. In short, when we used only 57 
genetic variants in the ADIPOQ locus only (our conservative approach) combining two 58 
extremely large datasets with over 60,000 CHD cases we find the causal odds ratio of a 59 
1 logged unit increase in adiponectin to be 0.97 (95% CI: 0.84, 1.12). There were no 60 
adjustments made in these analyses as we had already shown that the variants were 61 
not related to other risk factors and therefore these results cannot be ‘over adjusted’. 62 
Although animal studies suggest that adiponectin has cardio-protective effects, 63 
the picture has proven to be far more complicated in humans. Findings from 64 
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observational epidemiological studies on the association between adiponectin levels 65 
and risk of coronary heart disease (CHD) are conflicting8 and probably biased by 66 
residual confounding and reverse causality. Drugs, such as PPAR-γ (peroxisome 67 
proliferator-activated receptor gamma) agonists, that lead to changes in adiponectin 68 
levels, also act independently on multiple other pathways that likely influence CHD, 69 
and, therefore, their metabolic effects cannot be taken as evidence for causal effects 70 
of adiponectin. Mendelian randomization has successfully and increasingly been used 71 
in clinical research and can be a powerful tool to help unraveling mechanisms of 72 
disease and identifying potential drug targets, specially given the complex metabolic 73 
phenomena that commonly occur in human diseases. Our study builds on previous 74 
Mendelian randomization evidence by showing no consistent protective effect of 75 
adiponectin on cardiometabolic diseases3. 76 
The editorial by Turer and Scherer concludes that our results ‘should be treated 77 
with great caution’. However, we would argue that conclusions based on ‘correlational 78 
data’ from human studies, which they present as evidence for cardio-protection, merit 79 
the greatest caution, and that ‘preclinical evidence’ from animal studies lacks external 80 
validity and should not be assumed to translate to humans. Based on the multiple 81 
aspects explored in our analysis and the available evidence, we feel confident 82 
concluding that, currently, there is no consistent evidence that circulating adiponectin 83 
is more than an epiphenomenon in the context of CHD in humans. 84 
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